MedTrace Logo

Management of Acute Cardiogenic Shock at the New Brunswick Heart Centre

NCT05414643 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1416

Last updated 2022-06-10

No results posted yet for this study

Summary

In Atlantic Canada, acute myocardial infarction occurs at a rate of 2.9 % of the population and is the most common cause of cardiogenic shock (CS). In many studies, acute myocardial infarction accounts for up to 80% of the patients with CS. While there are different methods of treating patients with CS, the rate of mortality has not significantly improved over the years and remains as high as 50%. Recent studies have shown that a multi-modal, team-based approach can help improve patient outcomes; however, such a standardized approach is yet to be implemented in the New Brunswick Heart Centre (NBHC).

The study aims to understand the difference in outcomes between two groups of patients treated for CS: SHOCK TEAM versus non-SHOCK TEAM. This is a retrospective study of 168 patients using the data from NBHC registry and patient charts. The study duration is 1 year. The primary outcome is hospital survival. Secondary outcomes include time from diagnosis to invasive monitoring and intervention. All data will be analyzed statistically between the two groups. The end goal of the study is to establish standard guidelines to treat CS patients and improve patient survival.

Conditions

  • Cardiogenic Shock

Interventions

OTHER

Standard care

No interventions were used, as this is an observational study.

Sponsors & Collaborators

  • New Brunswick Heart Centre

    lead OTHER

Principal Investigators

  • Jean-François Légaré, M.D., Ph.D. · New Brunswick Heart Centre

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-14
Primary Completion
2021-10-13
Completion
2021-10-13

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05414643 on ClinicalTrials.gov